Pharmaceutical Research

, Volume 30, Issue 11, pp 2902–2916

Bioactive Lipids-Based pH Sensitive Micelles for Co-Delivery of Doxorubicin and Ceramide to Overcome Multidrug Resistance in Leukemia

  • Yongzhong Wang
  • Yunfei Ding
  • Ziming Liu
  • Xingrong Liu
  • Li Chen
  • Weili Yan
Research Paper

DOI: 10.1007/s11095-013-1121-5

Cite this article as:
Wang, Y., Ding, Y., Liu, Z. et al. Pharm Res (2013) 30: 2902. doi:10.1007/s11095-013-1121-5

ABSTRACT

Purpose

Construction of a novel PEGylated bioactive lipids-based micelle system for co-delivery of doxorubicin (DOX) and short chain ceramide (C6-ceramide) to overcome multidrug resistance in leukemia.

Methods

The PEGylated bioactive lipids-based micelle system was constructed via electrostatic and hydrophobic interactions among DOX, bioactive lipids PazPC and C6-ceramide. The micellar formulation was characterized in terms of size, zeta potential, stability and release behavior, etc., and in vitro cytotoxicity, in vivo antitumor efficacy and the underlying mechanism were further evaluated.

Results

This novel micellar system showed small size (~15 nm), high drug encapsulation efficiency (>90%), good stability and endosomal acid-triggered release of DOX. Synergistic cytotoxic effects between DOX and bioactive lipid C6-ceramide in P-gp overexpressing drug resistant leukemia P388/ADR cells were observed. The mechanistic studies demonstrated that modulation of drug efflux system and induction of apoptotic effects by lipids were responsible for the synergistic effects between DOX and C6-ceramide in drug resistant leukemia P388/ADR cells. Using an in-vivo P388/ADR leukemia mouse model, the median survival time of the DOX-loaded PEGylated micelles with PazPC and C6-ceramide as major components was significantly greater than that of free DOX and control group.

Conclusions

We developed a novel pH sensitive bioactive lipids-based micellar formulation which could potentially be useful in delivering chemotherapeutic drug DOX and provide a novel strategy to increase the therapeutic index for drug resistant leukemia treatment.

KEY WORDS

ceramide doxorubicin leukemia micelle oxidized phospholipid 

ABBREVIATIONS

DDS

Drug delivery system

DL%

Drug loading content

DLS

Dynamic light scattering

DOX

Doxorubicin hydrochloride

DPPC

Dipalmitoylphosphatidylcholine

DSPC

Distearoylphosphatidyl choline

DSPE-PEG2000

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000]

EE%

Encapsulation efficiency

ELS

Electrophoretic light scattering

ePC

Egg phosphatidylcholine

GCS

Glucosylceramide synthase

NBD-C6-ceramide

N-[6-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]hexanoyl]-D-erythro-sphingosine

OxPLs

Oxidized phospholipids

PazPC

1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine

PP/DOX

DOX-loaded PEG2000-DSPE/PazPC

PPC/DOX

DOX-loaded PEG2000-DSPE/PazPC/C6-ceramide

TUNEL

Terminal deoxynucleotidyl transferase dUTP nick end labeling

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Yongzhong Wang
    • 1
    • 2
  • Yunfei Ding
    • 3
  • Ziming Liu
    • 4
  • Xingrong Liu
    • 3
  • Li Chen
    • 1
  • Weili Yan
    • 3
  1. 1.Department of Pharmacal Sciences Harrison School of PharmacyAuburn UniversityAuburnUSA
  2. 2.School of Life SciencesAnhui UniversityHefeiChina
  3. 3.College of Life Sciences and EngineeringSouthwest Jiaotong UniversityChengduChina
  4. 4.West China Hospital, West China School of MedicineSichuan UniversityChengduChina